By Nathan Pennell, MD, PhD Posted: April 16, 2020 It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events